Device Trial Radar · NCT06167733
Safety and Efficacy of the VERTICA® RF Device for the Treatment of ED
Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
201
Actual
Start
Nov 29, 2023
Primary completion
Sep 21, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- OHH-MED Medical LtdNot on our public-company list
- Sponsor type
- Industry
- First posted
- Dec 12, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- Male only, from 22 years, up to 85 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Adult subjects with mild to moderate and moderate ED who meet the study eligibility criteria will be enrolled in the study. The enrolled subjects will be randomized by a 1:1 ratio to receive the Active or Sham VERTICA® treatment. Baseline assessments will include collection of demographic data, medical history, concomitant medications and baseline clinical examinations. The initial treatment session will be performed in a clinical setting simulating home use to determine proper device use and to evaluate device tolerability, followed by continued home use of the device for a total of 6 months. Patients will be instructed to attempt sexual activity periodically over the course of the study. Every time a sexual intercourse is attempted, the patient will be requested to complete an event log using validated assessments. Patients will present for monthly follow-up visits, during which safety will be evaluated and additional efficacy assessments will be performed.
Conditions
- Erectile Dysfunction
Interventions
VERTICA Active deviceDevice
VERTICA device with a therapeutic RF energy level
VERTICA Sham deviceDevice
VERTICA device with a low, non-therapeutic RF energy level
Primary outcomes
What the sponsor says the trial is designed to measure.
- A significant difference in the mean change from baseline in the International Index of Erectile Function - Erectile Function domain (IIEF-EF) scores at 12 weeks, between the treatment groups.Time frame: 12 weeks
- A significant change from baseline in the mean International Index of Erectile Function - Erectile Function domain (IIEF-EF) scores at 12 weeks, within the VERTICA Active treatment group.Time frame: 12 weeks
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
University of California, Irvine Medical Center
Newport Beach, California
San Diego Sexual Medicine
San Diego, California
Optimal Health Miami
Aventura, Florida
3 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.